PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

studied the tumors of patients who were treated with a drug called nivolumab in a clinical trial. The team collected samples from the patient tumors before treatment and, for some patients, after the ...

Opdivo Qvantig (nivolumab and hyaluronidase ... It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza ...

The Swiss drugmaker had hoped – despite spartalizumab coming to market well behind other PD-1/PD-L1 checkpoint inhibitors ... and Bristol-Myers Squibb’s Opdivo (nivolumab).

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

A COMBINATION of the anti-GDF-15 antibody visugromab and anti-PD-1 therapy nivolumab has shown promising results in overcoming resistance to immune checkpoint inhibition in patients with advanced ...

Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...